Aortic Valve Stenosis Clinical Trial
Official title:
Pilot Trial: Comparison of Flow Patterns. Is There a Difference Between sewed-in and "Sutureless" Bioprosthetic Aortic Heart Valves?
The purpose of this study is to determine why sutureless aortic bioprostheses apparently
offer better haemodynamic properties compared to sewed-in aortic bioprostheses in patients
who underwent aortic valve replacement.
Our approach to address this question is the combination of clinical data with the
application of specifically validated experimental and computer based analyses to compare the
performance of these valves under patient-specific conditions.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | December 2021 |
Est. primary completion date | December 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patient underwent open aortic valve replacement with either an Edwards Magna Ease or an Edwards Intuity valve - Implanted valve size 23mm - Surgical access via full sternotomy or hemisternotomy - Intuity Valve System implanted by one of the clinical investigators of the TRITON trial (http://clinicaltrials.gov/show/NCT01445171) at the Medical University of Vienna - Post-operative ejection fraction =50% - Sinus-Rhythm - Ability to understand and comply with study procedures - Signed informed consent Exclusion Criteria: - Under 18 years of age - Emergency surgery - Pregnancy - Previous aortic root replacement - Previous aortic valve replacement - Previous or concomitant root enlargement - Previous or concomitant repair of the ascending aorta - Paravalvular leakage - Ectasia of the ascending aorta - Previous or concomitant myomectomy - Concomitant replacement or repair of valves other than aortic - Usage of more than 3 sutures for implantation of the Intuity Valve System - Heavily calcified aortic root - Glomerular filtration rate (GFR) < 30 ml/min - Inability to understand or comply with study procedures - Known allergic reaction to iodinated, non-ionic contrast agents |
Country | Name | City | State |
---|---|---|---|
Austria | Medical University of Vienna | Vienna |
Lead Sponsor | Collaborator |
---|---|
Medical University of Vienna | University College, London |
Austria,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of maximum and minimum velocity under patient specific conditions | between 6 months and 4 years after aortic valve replacement | ||
Primary | Comparison of the effective orifice area under patient specific conditions | between 6 months and 4 years after aortic valve replacement | ||
Primary | Comparison of the percentage of turbulent flow under patient specific conditions | between 6 months and 4 years after aortic valve replacement | ||
Primary | Comparison of the pressure drop under patient specific conditions | between 6 months and 4 years after aortic valve replacement | ||
Secondary | Patient-specific, computer simulated pressure gradients compared to echocardiographically obtained pressure gradients. | The first secondary outcome measure is the comparison of -pressure gradients as computed by the model against the same data collected standardly with echocardiographic technique. Differences will be quantified. If positive (< 10%), this assessment would enhance the use of patient-specific models in clinics as a predictive tool for detailed haemodynamics." |
between 6 months and 4 years after aortic valve replacement | |
Secondary | Patient-specific, computer simulated peak velocity compared to echocardiographically obtained peak velocity. | The second secondary outcome measure is the comparison of -peak velocity as computed by the model against the same data collected standardly with echocardiographic technique. Differences will be quantified. If positive (< 10%), this assessment would enhance the use of patient-specific models in clinics as a predictive tool for detailed haemodynamics." |
between 6 months and 4 years after aortic valve replacement |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03186339 -
Validation of the "TASQ" in Patients Undergoing SAVR or TF-TAVI
|
||
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Terminated |
NCT02854319 -
REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System
|
N/A | |
Recruiting |
NCT05601453 -
The ReTAVI Prospective Observational Registry
|
||
Withdrawn |
NCT05481814 -
CPX in Paradoxical Low Flow Aortic Stenosis
|
||
Completed |
NCT02241109 -
Predicting Aortic Stenosis Progression by Measuring Serum Calcification Propensity
|
N/A | |
Completed |
NCT01700439 -
Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve
|
N/A | |
Recruiting |
NCT04429035 -
SLOW-Slower Progress of caLcificatiOn With Vitamin K2
|
N/A | |
Completed |
NCT04103931 -
Impact of a Patient Decision Aid for Treatment of Aortic Stenosis
|
N/A | |
Completed |
NCT03950440 -
Assessing the Incidence of Postoperative Delirium Following Aortic Valve Replacement
|
||
Active, not recruiting |
NCT02661451 -
Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)
|
N/A | |
Completed |
NCT02792452 -
Clinical Value of Stress Echocardiography in Moderate Aortic Stenosis
|
||
Completed |
NCT02758964 -
Evaluation of Cerebral Thrombembolism After TAVR
|
||
Completed |
NCT02847546 -
Evaluation of the BARD® True™ Flow Valvuloplasty Perfusion Catheter for Aortic Valve Dilatation
|
N/A | |
Not yet recruiting |
NCT02536703 -
Safety and Efficacy of Lotus Valve For TAVI In Patients With Severe Aortic Stenosis In Chinese Population
|
Phase 3 | |
Not yet recruiting |
NCT02541877 -
Sizing-sTrategy of Bicuspid AoRtic Valve Stenosis With Transcatheter Self-expandable Valve
|
Phase 3 | |
Completed |
NCT02249000 -
BIOVALVE - I / II Clincial Investigation
|
N/A | |
Not yet recruiting |
NCT02221921 -
Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI
|
N/A | |
Active, not recruiting |
NCT02080299 -
Protection by Remote Ischemic Preconditioning During Transcatheter Aortic Valve Implantation
|
Phase 2 | |
Terminated |
NCT01939678 -
Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease
|